Skip to content

Study · Not a test of the peptide alone · 2021

2 results

The effect of liraglutide on insulin allergy in a patient with glucocorticoid-induced diabetes and multiple sclerosis.

Zhang J, Chen Y, Wang J, Xia H, Zheng Y

Nagoya journal of medical science1 May 2021Cited by 2 (Europe PMC)

PMID34239182 (opens in a new tab)PMCIDPMC8236694 (opens in a new tab)DOI10.18999/nagjms.83.2.343 (opens in a new tab)PepBankPUB-34239182
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In a patient with glucocorticoid-induced diabetes and multiple sclerosis, switching to liraglutide combined with metformin improved glucose levels.

    In plain wordsIn one patient with steroid-induced diabetes, a switch to liraglutide plus metformin improved blood glucose.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedGlucose levels
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Here, we report a patient with SIDM and multiple sclerosis, for whom switching to liraglutide combined with metformin therapy improved glucose levels

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In a patient with glucocorticoid-induced diabetes and multiple sclerosis, switching to liraglutide combined with metformin ameliorated the symptoms of insulin allergy.

    In plain wordsIn one patient with steroid-induced diabetes, a switch to liraglutide plus metformin eased insulin allergy symptoms.

    Peptide
    Liraglutide
    Outcome
    DecreaseInsulin allergy symptoms
    Study

    n = 1

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Here, we report a patient with SIDM and multiple sclerosis, for whom switching to liraglutide combined with metformin therapy improved glucose levels and ameliorated the symptoms of insulin allergy

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.